Formulation Development
Longeveron Announces Contract Development & Manufacturing Business & First Contract
Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….
Aeterna Zentaris & Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….
uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation for Investigational Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AMT-130 for the treatment of…
PhoreMost Achieves Second Milestone in Target Discovery Alliance With Boehringer Ingelheim
PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel…
Anocca AB & Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
Anocca AB and Shinobi Therapeutics recently announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and…
Nxera Pharma & PrecisionLife Expand Strategic R&D Partnership Into New Therapeutic Area
Nxera Pharma Co. Ltd and PrecisionLife recently announced the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug…
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
Elevar Therapeutics, Inc. recently announced the landmark overall survival (OS) analysis of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) will…
Patient Dosing Commenced in Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients With Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announce patient dosing has commenced in the company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients…
Sanofi Completes Acquisition of Inhibrx, Inc.
Sanofi recently announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s…
Nxera Pharma to Receive $4.6 Million in Milestone Payments Rrom Centessa Pharmaceuticals
Nxera Pharma recently announced it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used…
Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of $3 Billion
This acquisition reflects the significant clinical progress achieved with Restoret, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as….
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals, Inc. recently announced a major advancement in the battle against obesity. The company has achieved a significant milestone by officially filing a provisional patent application covering formulations that….
Vyluma Announces Marketing Authorization Application Validation for the European Union
Vyluma, Inc. recently announced the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for its lead compound, NVK002. The application is confirmed…
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine…
Evonik Drives Sustainable Biosurfactant Revolution With Inauguration of New Facility in Slovakia
First facility worldwide to manufacture industrial-scale rhamnolipid biosurfactants; huge potential in personal care, cleaning, coatings, animal nutrition, agriculture, and many other applications….
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation From the EMA for the Treatment of Chronic Hepatitis D
Bluejay Therapeutics recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for orphan designation for BJT-778 for the…
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
ProBioGen recently announced a pivotal collaboration with ModeX Therapeutics an OPKO Health Company dedicated to combating cancer and infectious diseases with cutting-edge….
RespireRx Announces DoD Award to Fund Phase 2 Clinical Study to Determine Safety & Efficacy of its Lead AMPAkine to Improve Bladder Function in Patients With Spinal Cord Injury
RespireRx Pharmaceuticals Inc. recently announced the Department of Defense (DoD) has approved a $1.8-million translational research award to Shirley Ryan AbilityLab to fund a two-stage…
Artelo Biosciences Presents Highly Encouraging Data Toward Developing Solid Dosage Form of ART12.11
Artelo Biosciences, Inc. recently announced Dr. Andrew Yates presented new preclinical data on ART12.11 at the CT-CANN24 conference held May 29-30, 2024, at the Hilton…
Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS
Spinogenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for its Phase 1/2 clinical trial of SPG302 for the…
